The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical ...
Abstract: This 1 paper 2 solves an enhanced adaptive dynamic programming (ADP)-based collision-free enclosing learning control for Unmanned Aerial Vehicles (UAVs) to move around a specified target ...
ZEELAND, MI, UNITED STATES, February 26, 2026 /EINPresswire.com/ — The Additive Manufacturing Users Group (AMUG) today announced a second keynote presentation for ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on ...
Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results